2.03
Precedente Chiudi:
$2.03
Aprire:
$1.9923
Volume 24 ore:
5,698
Relative Volume:
0.28
Capitalizzazione di mercato:
$13.34M
Reddito:
-
Utile/perdita netta:
$-7.72M
Rapporto P/E:
-0.7691
EPS:
-2.6394
Flusso di cassa netto:
$-6.25M
1 W Prestazione:
+1.50%
1M Prestazione:
+3.57%
6M Prestazione:
+20.83%
1 anno Prestazione:
-53.76%
Edesa Biotech Inc Stock (EDSA) Company Profile
Nome
Edesa Biotech Inc
Settore
Industria
Telefono
(905) 475-1234
Indirizzo
100 SPY COURT, MARKHAM, ON
Confronta EDSA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
EDSA
Edesa Biotech Inc
|
2.03 | 13.34M | 0 | -7.72M | -6.25M | -2.6394 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Edesa Biotech Inc Borsa (EDSA) Ultime notizie
Edesa Biotech secures up to C$23 million in funding under the Federal Government’s Strategic Innovation Fund for pivotal clinical study - Fasken
Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares - Fasken
40,944 Shares in Edesa Biotech, Inc. (NASDAQ:EDSA) Bought by Citadel Advisors LLC - Defense World
Edesa Biotech Shareholders Approve Key Proposals at AGM - TipRanks
Edesa Biotech (EDSA) Receives Buy Rating from Lucid Capital | ED - GuruFocus
Zacks Small Cap Reduces Earnings Estimates for Edesa Biotech - Defense World
EDSA: Advancing EB06 for the Treatment of Vitiligo - Research Tree
EDSA: Advancing EB06 for the Treatment of Vitiligo… - Yahoo Finance
Positive Signs As Multiple Insiders Buy Edesa Biotech Stock - Yahoo Finance
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results - GlobeNewswire
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025 - TipRanks
Edesa Biotech Q2 EPS USD -0.3 - marketscreener.com
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech Reports Q2 2025 Financial Results and Advances Vitiligo Drug Development Efforts - Nasdaq
Edesa Biotech Advances Novel Vitiligo Treatment with $15M Backing from Healthcare Investors - Stock Titan
Edesa Biotech Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Edesa Biotech (EDSA) to Release Quarterly Earnings on Friday - Defense World
Edesa Biotech to Present at 2024 Bloom Burton Healthcare Investor Conference - TipRanks
Edesa Biotech to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto - Nasdaq
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference - GlobeNewswire
Edesa Biotech Showcases Immuno-Inflammatory Pipeline at Bloom Burton Healthcare Conference - Stock Titan
Edesa Biotech (NASDAQ:EDSA) Shares Up 3% – Time to Buy? - Defense World
Healthcare Veteran Returns to NeuPath as President, Armed with Ambitious Expansion Plan - Stock Titan
Edesa Biotech secures $15 million for clinical program - MSN
Edesa Biotech (NASDAQ:EDSA) and Earth Science Tech (OTCMKTS:ETST) Head-To-Head Review - Defense World
Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO - MSN
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Edesa Biotech Announces Chief Financial Officer Transition - GlobeNewswire
Edesa Biotech announces CFO transition - MSN
Edesa Biotech names Peter Weiler as new CFO By Investing.com - Investing.com South Africa
Edesa Biotech (EDSA) Shares Drop After New CFO Announcement - GuruFocus
Edesa Biotech Appoints New CFO Amid Leadership Change - TipRanks
Edesa Biotech names Peter Weiler as new CFO - Investing.com
Edesa Biotech Hires Peter Weiler From Exzell Pharma to be New CFO - marketscreener.com
Edesa Biotech, Inc. Announces Chief Financial Officer Changes, Effective May 1, 2025 - MarketScreener
HC Wainwright Comments on Edesa Biotech Q2 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Edesa Biotech (NASDAQ:EDSA) - Defense World
H.C. Wainwright maintains $21 target on Edesa Biotech shares By Investing.com - Investing.com Australia
H.C. Wainwright maintains $21 target on Edesa Biotech shares - Investing.com India
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - The Globe and Mail
Edesa Biotech completes US$15 million private placement - Fasken
You Won't Believe What Nvidia CEO Jensen Huang Just Said - The Globe and Mail
Edesa Biotech files to sell 7.81M common shares for holders - MSN
Nvidia Stock Isn’t So Magnificent Anymore. Is It Time to Sell Shares Now? - The Globe and Mail
Zacks Small Cap Boosts Earnings Estimates for Edesa Biotech - Defense World
EDSA: Raises 15 Million to Advance EB06 - Smartkarma
EDSA: Raises $15 Million to Advance EB06… - Yahoo Finance
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
Biotech Stocks To Keep An Eye On – February 13th - Defense World
Edesa Biotech Inc Azioni (EDSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):